Is KLRS or IFRX more profitable?

InflaRx's return on equity of -53.56% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% InflaRx N/A -53.56% -43.02%

Do analysts recommend NLTX or KLRS?

Kalaris Therapeutics has a consensus target price of $18.75, indicating a potential upside of 740.81%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kalaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable earnings & valuation, NLTX or KLRS?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.02 N/A

Is NLTX or KLRS more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Kalaris Therapeutics N/A -71.71% -42.95%

Kalaris Therapeutics (KLRS) Competitors

$2.23 -0.03 (-1.33%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$2.26 +0.04 (+1.57%)

As of 04:02 AM Eastern

Compare

KLRS vs. ANIK, IFRX, STRO, CAMP, and NLTX

Should you buy Kalaris Therapeutics stock or one of its competitors? Kalaris Therapeutics's main competitors and comparable companies include Anika Therapeutics (ANIK), InflaRx (IFRX), Sutro Biopharma (STRO), CAMP4 Therapeutics (CAMP), and Neoleukin Therapeutics (NLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kalaris Therapeutics compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

In the previous week, Anika Therapeutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for Anika Therapeutics and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.82 beat Anika Therapeutics' score of 1.44 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anika Therapeutics	Positive
Kalaris Therapeutics	Very Positive

Anika Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.43	-$10.88M	-$0.27	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Kalaris Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Anika Therapeutics currently has a consensus price target of $22.00, indicating a potential upside of 7.16%. Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 740.81%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Anika Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Anika Therapeutics and Kalaris Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Kalaris Therapeutics compare to InflaRx?

Kalaris Therapeutics (NASDAQ:KLRS) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Kalaris Therapeutics has higher earnings, but lower revenue than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A
InflaRx	$30K	7,614.12	-$51.63M	-$0.58	N/A

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

InflaRx's return on equity of -53.56% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
InflaRx	N/A	-53.56%	-43.02%

Kalaris Therapeutics currently has a consensus target price of $18.75, indicating a potential upside of 740.81%. InflaRx has a consensus target price of $7.43, indicating a potential upside of 379.26%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

Kalaris Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.59, indicating that its stock price is 159% more volatile than the broader market.

In the previous week, InflaRx had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for InflaRx and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.82 beat InflaRx's score of 1.60 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kalaris Therapeutics	Very Positive
InflaRx	Very Positive

Summary

Kalaris Therapeutics beats InflaRx on 8 of the 14 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Sutro Biopharma?

Sutro Biopharma (NASDAQ:STRO) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Sutro Biopharma currently has a consensus price target of $49.50, indicating a potential upside of 349.59%. Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 740.81%. Given Kalaris Therapeutics' higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 1.8% of Sutro Biopharma shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Sutro Biopharma has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

Kalaris Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Kalaris Therapeutics has lower revenue, but higher earnings than Sutro Biopharma. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	1.78	-$191.09M	-$11.97	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

In the previous week, Sutro Biopharma had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 2 mentions for Sutro Biopharma and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.82 beat Sutro Biopharma's score of 1.26 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sutro Biopharma	Positive
Kalaris Therapeutics	Very Positive

Summary

Sutro Biopharma beats Kalaris Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to CAMP4 Therapeutics?

CAMP4 Therapeutics (NASDAQ:CAMP) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Kalaris Therapeutics has lower revenue, but higher earnings than CAMP4 Therapeutics. CAMP4 Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CAMP4 Therapeutics	$3.50M	61.50	-$80.40M	-$2.32	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

CAMP4 Therapeutics presently has a consensus price target of $10.86, indicating a potential upside of 216.53%. Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 740.81%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

66.1% of Kalaris Therapeutics shares are owned by institutional investors. 21.7% of CAMP4 Therapeutics shares are owned by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CAMP4 Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Kalaris Therapeutics has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. Kalaris Therapeutics' return on equity of -71.71% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

In the previous week, CAMP4 Therapeutics had 2 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 3 mentions for CAMP4 Therapeutics and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.82 beat CAMP4 Therapeutics' score of 0.64 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CAMP4 Therapeutics	Positive
Kalaris Therapeutics	Very Positive

Summary

Kalaris Therapeutics beats CAMP4 Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.02	N/A

Kalaris Therapeutics has a consensus target price of $18.75, indicating a potential upside of 740.81%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Neoleukin Therapeutics' return on equity of -37.22% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Kalaris Therapeutics and 0 mentions for Neoleukin Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.82 beat Neoleukin Therapeutics' score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Kalaris Therapeutics	Very Positive

Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

Summary

Kalaris Therapeutics beats Neoleukin Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$53.80M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.43	199.17	19.37
Price / Sales	N/A	1,157.81	564.77	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.53	16.93	10.70	6.03
Net Income	-$43.44M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-12.89%	-4.41%	-2.89%	-2.32%
1 Month Performance	-32.42%	-12.46%	-7.36%	-5.29%
1 Year Performance	-56.27%	7.64%	3.00%	-2.94%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	2.5505 of 5 stars	$2.23 -1.3%	$18.75 +740.8%	-53.2%	$53.80M	N/A	N/A	20	Positive News
ANIK Anika Therapeutics	3.1755 of 5 stars	$19.04 -1.7%	$22.00 +15.6%	+125.6%	$255.18M	$112.82M	N/A	235	Positive News
IFRX InflaRx	2.149 of 5 stars	$1.73 +0.9%	$7.43 +330.6%	+24.0%	$254.21M	$30K	N/A	65	Positive News
STRO Sutro Biopharma	3.6072 of 5 stars	$15.09 -5.5%	$49.50 +228.0%	+32.9%	$251.02M	$102.48M	N/A	128	Positive News
CAMP CAMP4 Therapeutics	3.3042 of 5 stars	$4.00 +4.2%	$10.17 +154.0%	-4.5%	$250.69M	$3.50M	N/A	644

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. ANIK, IFRX, STRO, CAMP, and NLTX

How does Kalaris Therapeutics compare to Anika Therapeutics?

Summary

How does Kalaris Therapeutics compare to InflaRx?

Summary

How does Kalaris Therapeutics compare to Sutro Biopharma?

Summary

How does Kalaris Therapeutics compare to CAMP4 Therapeutics?

Summary

How does Kalaris Therapeutics compare to Neoleukin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. ANIK, IFRX, STRO, CAMP, and NLTX

How does Kalaris Therapeutics compare to Anika Therapeutics?

Does the media favor ANIK or KLRS?

Which has stronger earnings & valuation, ANIK or KLRS?

Is ANIK or KLRS more profitable?

Do analysts rate ANIK or KLRS?

Which has more risk and volatility, ANIK or KLRS?

Do institutionals and insiders believe in ANIK or KLRS?

Summary

How does Kalaris Therapeutics compare to InflaRx?

Which has preferable earnings & valuation, KLRS or IFRX?

Do institutionals and insiders have more ownership in KLRS or IFRX?

Is KLRS or IFRX more profitable?

Do analysts prefer KLRS or IFRX?

Which has more volatility and risk, KLRS or IFRX?

Does the media refer more to KLRS or IFRX?

Summary

How does Kalaris Therapeutics compare to Sutro Biopharma?

Do analysts prefer STRO or KLRS?

Do institutionals & insiders believe in STRO or KLRS?

Which has more risk & volatility, STRO or KLRS?

Is STRO or KLRS more profitable?

Which has higher valuation & earnings, STRO or KLRS?

Does the media favor STRO or KLRS?

Summary

How does Kalaris Therapeutics compare to CAMP4 Therapeutics?

Which has higher valuation and earnings, CAMP or KLRS?

Do analysts recommend CAMP or KLRS?

Do institutionals and insiders believe in CAMP or KLRS?

Which has more risk & volatility, CAMP or KLRS?

Is CAMP or KLRS more profitable?

Does the media favor CAMP or KLRS?

Summary

How does Kalaris Therapeutics compare to Neoleukin Therapeutics?

Which has preferable earnings & valuation, NLTX or KLRS?

Do analysts recommend NLTX or KLRS?

Is NLTX or KLRS more profitable?

Do insiders and institutionals believe in NLTX or KLRS?

Does the media favor NLTX or KLRS?

Which has more volatility & risk, NLTX or KLRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools